In This Article:
RBC Capital notes that CorMedix (CRMD) announced preliminary Q1 2025 revenues for DefenCath of $39M, with an increase to first half of 2025 revenue guidance now at $62M-$70M, from $50M-$60M, off strong orders through early-March. As previously anticipated, Q2 orders are to be lower than Q1, due to the timing of shipments between customers – though encouragingly, management believes utilization is likely to continue to trend up, anticipating a stronger second half of the year, RBC adds. This morning’s pre-report offers some reassurance for the ongoing DefenCath launch, particularly during a time of market/macro uncertainty and volatility, the firm argues. RBC maintains an Outperform rating on the shares with a price target of $12.
Stay Ahead of the Market:
-
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
-
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRMD: